2025年司帕生坦最新价格是多少钱一盒？

Sparsentan is an innovative drug for the treatment of primary immunoglobulin A nephropathy (IgAN). Its price and accessibility have always been a focus of concern for patients. This article will detail the latest price information, global launch status and necessary preparations before taking the drug of sparsentan in 2025 to help patients fully understand this important treatment option.

What is the latest price of a box of Sparsentan in 2025?

The market price in 2025 remains relatively stable, with significant differences between different versions.

Price of the original drug in the United States

The original drug Filspari produced by Travere Therapeutic in the United States has a specification of 400mg*30 tablets/box. The reference price in 2025 is approximately US$15,277.

Prices of generic drugs in Laos

The generic drugs produced by Lucius in Laos are 400mg*30 tablets/box, and the reference price is about US$808 per box.

Factors affecting price

Drug prices are affected by multiple factors such as raw material costs, patent protection, market competition and exchange rate fluctuations. As more generic drug companies enter the market, prices are expected to drop further in the future.

Patients can choose a suitable version of the drug based on their financial situation and treatment needs.

The global launch of spasentan

The global launch of spasentan is progressing steadily, but the progress is uneven in various regions.

U.S. market

As the first country to be approved, the United States approved sparsentan for the treatment of IgAN in February 2023. The drug will have a stable supply in the U.S. market in 2025 and will be included in some commercial insurance plans.

European market

The EU EMA will complete the review at the end of 2024, and it is expected to obtain marketing authorization in the first half of 2025. There is already limited access in the UK through the early access scheme.

Asian Market

Clinical trials are ongoing in Japan and South Korea and are expected to be approved in 2026. China has not yet launched registration applications, and patients currently mainly rely on cross-border purchases.

The advancement of the global launch process will gradually improve drug accessibility and bring treatment hope to more patients.

Preparation for taking sparsentan

Full preparation is required before starting sparsentan treatment.

Medical evaluation

Liver function test, pregnancy test (for female patients) and basic renal function assessment must be completed before treatment. It is recommended to improve urine protein quantification and renal pathological examination to clarify the diagnosis and disease staging.

Drug acquisition

Obtain drugs through formal channels, check the integrity of drug packaging, and check the batch number and production date. Keep the purchase receipt and drug instructions for follow-up and adverse reaction reporting.

Before starting treatment, you should control your blood pressure, adjust your diet (low salt, high-quality protein), and prepare a home blood pressure monitor and weight scale for daily monitoring. Understand possible adverse reactions and countermeasures.